Research Article

Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare

Table 3

Multivariate analysis—CHOP patients only.

Total Cost
Coef.95% CI
LowerUpper

First-line therapy
 Chemotherapy alone
 Rituximab plus chemotherapy$20,971$9,089$32,659
Age at diagnosis (years)
 66–70
 71–75 $ 2,912 $ 1 5,466$8,729
 76–80$773 $ 11,864$13,465
 >80 $ 7,929 $ 22,218$7,109
Gender
 Male
 Female $ 3,782 $ 1 3,154$5,274
Race/ethnicity
 White
 Black$8,251 $ 3 1,012$52,301
 Hispanic$21,353 $ 9,712$55,955
 Other $ 2 5,380 $ 4 5,449 $ 3,296
Year of diagnosis
 1999–2002
 2003–2005 $ 1,968 $ 6,478$2,424
Stage at FL diagnosis
 I & II
 III & IV$13,947$3,943$23,806
Histology (grade)
 1
 2$1,440 $ 1 4,298$18,830
 3 $ 4,210 $ 1 8,063$10,882
 4 $ 6,924 $ 2 0,108$6,774
Extranodal involvement
 No
 Yes$16,683$6,307$27,617
Presence of “B” symptoms
 No
 Yes$7,654−$6,707$21,571
Anemia
 No
 Yes$24,622−$7,946$62,434
NCI Comorbidity index
 0
 1$7,999−$3,871$19,294
 2$7,787−$8,899$26,799
 ≥3$60,399−$13,310$137,762
Performance status indicators
 None
 ≥1$10,882−$5,310$26,939
Percent in census tract with some college
 <25%
 ≥25%−$4,875−$15,504$5,380
Percent in census tract living in poverty
 <5%
 5–7%$2,021−$12,003$17,365
 8–12%$5,296−$7,066$17,032
 >12%$7,107−$5,484$18,882
Type of geographic area
 Large metropolitan
 Metropolitan−$6,202−$16,529$4,807
 Urban−$14,949−$33,514$3,791
 Less urban/rural−$13,777−$27,682$49